Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05079230 · ClinicalTrials.gov registry record · Phase 3
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
A Phase 3 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 378
- Enrollment target
NCT05079230 is a Phase 3 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 378 participants.
The verdict
NCT05079230, a Phase 3 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 378 participants
- Enrollment target
Study Summary
The goal of this clinical study is to compare the study drugs, magrolimab + venetoclax + azacitidine, versus placebo + venetoclax + azacitidine in participants with untreated acute myeloid leukemia (AML) who are not able to have chemotherapy.
Interventions
- DRUG Venetoclax
- DRUG Placebo
- DRUG Azacitidine
- DRUG Magrolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 378 participants |
| Start Date | 2022-07-07 |
| Est. Completion | 2024-04-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05079230
The ClinicalTrials.gov registry entry for NCT05079230 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 378 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Venetoclax is the first listed.
NCT05079230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05079230 about?
NCT05079230 is a clinical study titled "Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia". The goal of this clinical study is to compare the study drugs, magrolimab + venetoclax + azacitidine, versus placebo + venetoclax + azacitidine in participants with untreated acute myeloid leukemia (AML) who are not able to have chemotherapy.
What is the current status of trial NCT05079230?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 378 participants. The study started on 2022-07-07. Estimated completion is 2024-04-11.
What interventions are being tested in trial NCT05079230?
The interventions under investigation include: Venetoclax (DRUG), Placebo (DRUG), Azacitidine (DRUG), Magrolimab (DRUG).
Who is sponsoring clinical trial NCT05079230?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.